Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4.65 CAD | -1.69% | -6.06% | +17.72% |
08/04 | HLS Therapeutics Inc. Announces Reduce-IT Analysis Results Relating the Effects of VASCEPA | CI |
14/03 | Transcript : HLS Therapeutics Inc., Q4 2023 Earnings Call, Mar 14, 2024 |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses
- The company has insufficient levels of profitability.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+17.72% | 108M | D | ||
+15.89% | 71.39B | C+ | ||
+1.64% | 25.1B | C+ | ||
-1.22% | 8.59B | C | ||
+6.69% | 8.19B | B | ||
-20.96% | 7.91B | B- | ||
+17.12% | 4.31B | B+ | ||
-3.38% | 3.93B | B- | ||
-3.02% | 3.86B | B | ||
+22.08% | 3.64B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- HLS Stock
- Ratings HLS Therapeutics Inc.